Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2021-05-26 Earnings Release
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
PR_2021-05-26_BOTHE_2021-Q1_FR_Final.pdf
Earnings Release Classification · 98% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATION RÉGLEMENTÉE" (Press Release – Regulated Information) and announces the company's activities for the "premier trimestre 2021" (first quarter of 2021), concluding March 31, 2021. It provides key operational updates (clinical trials, partnerships) and preliminary financial elements (cash position, expected burn rate) for the period. This structure—a press release summarizing quarterly performance highlights and outlook—is the defining characteristic of an Earnings Release (ER). It is not the comprehensive 'Interim Report' (IR) itself, but the initial announcement of the results. The document length (13,961 chars) is substantial, but the format is clearly that of a summary announcement rather than a full regulatory filing like a 10-K or IR. Q1 2021
2021-05-26 French
5FR.Politique de rémunération 2021.pdf
Remuneration Information Classification · 98% confidence The document is titled "Politique de rémunération" (Remuneration Policy) and extensively details the compensation structure for both the Board of Directors (Conseil d'administration) and the Executive Committee (Comité exécutif). It discusses fixed pay, variable incentives (STI), pension plans, long-term incentive plans (warrants), and compliance with Belgian corporate law regarding executive compensation. This content directly aligns with the definition of a report detailing compensation for top executives and directors, which corresponds to the 'Remuneration Information' category.
2021-05-07 French
7.Rapport de gestion 2020 Bone Therapeutics.pdf
Annual Report Classification · 95% confidence The document is a 'Rapport de gestion du Conseil d'administration' (Management Report of the Board of Directors) covering the fiscal year ending December 31, 2020. It includes detailed strategic developments, operational updates, and financial statements (income statement tables). While it functions as a management report, it contains the core financial data and analysis for the annual period, fitting the definition of an Annual Report (10-K equivalent in this context). FY 2020
2021-05-07 French
1EN.Bone Therapeutics_convening notice AGM 20210609.pdf
AGM Information Classification · 98% confidence The document explicitly uses the heading "CONVOCATION TO THE ORDINARY GENERAL MEETING HELD ON 9 JUNE 2021". It details the agenda for this meeting, which includes deliberation on the 2020 annual accounts, remuneration reports, director discharges, and renewal of director mandates. This content is characteristic of a notice or proxy statement for an Annual General Meeting (AGM). The definition for AGM Information (AGM-R) covers "Presentations and materials shared during the Annual General Meeting (AGM)". While this is a convocation notice, it serves as the primary material related to the AGM proceedings, making AGM-R the most appropriate classification over a general Regulatory Filing (RNS) or Proxy Solicitation (PSI), as the focus is clearly on convening the meeting itself.
2021-05-07 English
6.Comptes annuels_2020 final.PDF
Annual Report Classification · 100% confidence The document is a formal Belgian 'Comptes Annuels' (Annual Accounts) filing for the company 'Bone Therapeutics'. It contains detailed balance sheet data, identification information, and a list of directors, which are standard components of a statutory annual financial report. Since it provides comprehensive financial statements for the fiscal year, it is classified as an Annual Report (10-K equivalent in this context). FY 2020
2021-05-07 French
2EN.Bone Therapeutics_Proxy form_ AGM_ENG.pdf
Proxy Solicitation & Information Statement Classification · 99% confidence The document is explicitly titled 'PROXY FORM' and details the process for a shareholder to appoint a proxy holder to vote on their behalf at an 'ordinary general meeting' (AGM) scheduled for June 9, 2021. It includes the agenda items, which cover approval of annual accounts, remuneration reports, and director discharges. This document is the material used to solicit shareholder votes and appoint representation for the AGM, which directly corresponds to the definition of a Proxy Solicitation & Information Statement.
2021-05-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.